Literature DB >> 23954710

Comparison of transduction efficiency among various lentiviruses containing GFP reporter in bone marrow hematopoietic stem cell transplantation.

Nan Wang1, Narendiran Rajasekaran, Tieying Hou, Leszek Lisowski, Elizabeth D Mellins.   

Abstract

HIV-derived lentiviral vectors have been used widely to transduce non-dividing cells, such as hematopoietic stem cells (HSCs), in the setting of gene therapy. In this study, we screened lentiviral vectors for their ability to drive expression of the murine MHC class II chaperone, invariant chain (Ii) and a GFP reporter. The vectors included T2A vector with T2A-separated Ii and GFP under the same MSCV promoter, dual-promoter vectors with separate promoters for Ii and GFP (called MSCV or EF1a according to the promoter driving Ii expression), and a vector with EF1a driving a fusion of Ii/GFP (called Fusion vector). T2A and MSCV induced the highest levels of Ii and GFP expression, respectively, after direct transfection of 293T cells. All vectors except the Fusion vector drove expression of functional Ii, based on the enhancement of MHC class II level, which is a known consequence of Ii expression. Comparing the vectors after they were packaged into lentiviruses and used to transduce 293T, we found that MSCV and EF1a vectors mediated higher Ii and GFP expression. In ckit(+) bone marrow (BM) cells, MSCV still induced the highest Ii and GFP expression, whereas EF1a induced only robust Ii expression. Regardless of the vector, both Ii and GFP levels were significantly reduced in BM cells compared to 293T cells. When in vivo expression was assessed in cells derived from MSCV-transduced BM-HSCs, up to 80% of myeloid cells were GFP(+), but no Ii expression was observed. In contrast, transplantation of EF1a-transduced BM-HSCs led to much higher in vivo Ii expression. Thus, among those compared, dual-promoter vector-based lentivirus with the EF1a promoter driving the gene of interest is optimal for murine BM-HSC transduction.
Copyright © 2013 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23954710      PMCID: PMC3833897          DOI: 10.1016/j.exphem.2013.07.002

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  33 in total

1.  Hybrid HIV/MSCV LTR enhances transgene expression of lentiviral vectors in human CD34(+) hematopoietic cells.

Authors:  J K Choi; N Hoang; A M Vilardi; P Conrad; S G Emerson; A M Gewirtz
Journal:  Stem Cells       Date:  2001       Impact factor: 6.277

Review 2.  Polycistronic viral vectors.

Authors:  P de Felipe
Journal:  Curr Gene Ther       Date:  2002-09       Impact factor: 4.391

Review 3.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 4.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

5.  I-Ag7 is subject to post-translational chaperoning by CLIP.

Authors:  Cornelia H Rinderknecht; Ning Lu; Oliver Crespo; Phi Truong; Tieying Hou; Nan Wang; Narendiran Rajasekaran; Elizabeth D Mellins
Journal:  Int Immunol       Date:  2010-06-13       Impact factor: 4.823

6.  Lentivirus-based vectors transduce mouse hematopoietic stem cells with similar efficiency to moloney murine leukemia virus-based vectors.

Authors:  S Barrette; J L Douglas; N E Seidel; D M Bodine
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

7.  Silencing of proviruses in embryonic cells: efficiency, stability and chromatin modifications.

Authors:  Sharon Schlesinger; Stephen P Goff
Journal:  EMBO Rep       Date:  2012-11-16       Impact factor: 8.807

8.  Identification of parameters required for efficient lentiviral vector transduction and engraftment of human cord blood CD34(+) NOD/SCID-repopulating cells.

Authors:  Ying Liu; Giao Hangoc; Timothy B Campbell; Michael Goodman; Wen Tao; Karen Pollok; Edward F Srour; Hal E Broxmeyer
Journal:  Exp Hematol       Date:  2008-08       Impact factor: 3.084

9.  Hematopoietic stem cell gene therapy: selecting only the best.

Authors:  Arthur Bank
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

10.  Lentiviral transduction of CD34(+) cells induces genome-wide epigenetic modifications.

Authors:  Yoshiaki Yamagata; Véronique Parietti; Daniel Stockholm; Guillaume Corre; Catherine Poinsignon; Nizar Touleimat; Damien Delafoy; Céline Besse; Jörg Tost; Anne Galy; András Paldi
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

View more
  4 in total

1.  Transgene expression in various organs post BM-HSC transplantation.

Authors:  Nan Wang; Narendiran Rajasekaran; Tieying Hou; Elizabeth D Mellins
Journal:  Stem Cell Res       Date:  2013-11-02       Impact factor: 2.020

2.  Immunological Basis for Rapid Progression of Diabetes in Older NOD Mouse Recipients Post BM-HSC Transplantation.

Authors:  Nan Wang; Narendiran Rajasekaran; Tieying Hou; Claudia Macaubas; Elizabeth D Mellins
Journal:  PLoS One       Date:  2015-05-28       Impact factor: 3.240

Review 3.  Induced pluripotent stem cells in hematology: current and future applications.

Authors:  D Focosi; G Amabile; A Di Ruscio; P Quaranta; D G Tenen; M Pistello
Journal:  Blood Cancer J       Date:  2014-05-09       Impact factor: 11.037

Review 4.  The Chimeric Antigen Receptor Detection Toolkit.

Authors:  Yifei Hu; Jun Huang
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.